+44 (0)1865-842-976 (UK)

+91 20 30108 270 (ASIA)

In recent years, the field of immuno-oncology has become one of the most promising and fastest growing areas of cancer research with many drugs introduced in the market and many more in the pipeline of different pharmaceutical companies. Immuno-oncology has become a sub-specialty within oncology owing to its unique science and its potential for substantial and long-term clinical benefit. This success is based on progress in both preclinical and clinical development of first and second generation of therapeutics using different molecules and immune system that include Antibody drug conjugates, bispecific antibodies, immune checkpoint blockades, adoptive cellular therapy.

Despite the growth much more research is needed to understand the breadth of opportunities these new generations of immunotherapies represent.

Next Gen Immuno-Oncology Congress to be held on 13th and 14th March 2017  in London, UK aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the growth of existing therapeutics and pave way for emerging next generation therapeutics. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced.

conference Registration Form



Academic Delegate£495
Industry Delegate £695
Solution Provider Delegate£1199


Key Highlights:

  • Translational and Clinical Insights
  • Emerging development Linker and conjugation technologies
  • PK/PD, efficacy, specificity and stability of cytotoxins and payloads
  • Targeted  therapeutics of Cancer therapies
  • Tumor Microenvironment
  • Biomarkers and combination therapy: Future prospects
  • Immune Checkpoint Blockade in Cancer Therapy: News insights, opportunities, and prospects for a Cure
  • Personalizing cancer treatment- Challenges and opportunities 

Who Should Attend ?

From Pharmaceutical, biopharmaceutical, biotechnology and research institutes:

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group leaders, Professor, Assistant professors, Research fellow, PhD working on

Antibody drug conjugates           Bispecific Antibodies                         Immune checkpoint inhibitors

  • ADCs development Preclinical and Translational Oncology
  • Oncology
  • Clinical development
  • R&D- Discovery and process
  • Antibody Engineering
  • Antibody therapeutics
  • Physio-Chemistry /Synthetic Chemistry and/ Bio conjugation
  • Bi-specifics- Preclinical and Translational Oncology
  • Oncology
  • Clinical development
  • R&D- discovery and process
  • Discovery
  • Target Validation
  • Bioanalysis
  • Therapeutic areas
  • Biologics -antibody

  • Cancer immunotherapy
  • Immune checkpoint targets
  • Checkpoint inhibition
  • Cellular therapy
  • Clinical research
  • Combination therapy
  • Cancer Vaccines
  • Preclinical and Translational Oncology R&D
  • Immune biomarkers
  • Immunology
  • Cancer biology
  • Immuno-oncology
  • Innate and adaptive immune cells
  • Tumour-associated mechanisms of immune suppression
  • Cell-Based Immunotherapies
  • Antibody engineering
  • Tumour antigens and neoantigens


Why Attend?

  • Find out new case studies of antibody projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session 

Advisory Panel

  • Dr. Eugene Zhukovsky
    Chief Scientific Officer
    BIOMUNEX Pharmaceuticals, France
  • Dr. A. Graham Pockley, PhD
    Associate Director
    John van Geest Cancer Research Centre, Nottingham Trent University, London - United Kingdom
  • Prof. Gabriele Multhoff, PhD 
    Department of Radiation Oncology, 
    Klinikum rechts der Isar, TU München, Munich and HMGU Munich 


  • Dr. Eugene Zhukovsky

    Chief Scientific Officer, BIOMUNEX Pharmaceuticals, France
  • Dr. A. Graham Pockley

    Associate Director, John van Geest Cancer Research Centre, Nottingham Trent University, London UK
  • Dr. Sophia N. Karagiannis

    Head of Cancer Antibody Discovery and Immunotherapy Division of Genetics and Molecular Medicine, Kings College London
  • Dr. Matthias Friedrich

    Scientific Director, Nonclinical Development AMGEN Research (Munich) GmbH
  • Prof. Kris Thielemans

    Head-Laboratory of Molecular & Cellular Therapy, Vrije Universiteit Brussel (VUB), Faculty of Medicine & Pharmacy
  • Dr. Helmout Modjtahedi

    Professor of Cancer Biology, Director of Cancer Research Group, Kingston University London
  • Dr. Robert Hawkins

    Director and Professor of Medical Oncology University of Manchester and Christie Hospital.
  • Dr. Darren Schofield

    Senior Research Scientist, MedImmune
  • Prof. Lindy Durrant

    Cancer Immunotherapy, Faculty of Medicine & Health Sciences Academic Clinical Oncology, The University of Nottingham
  • Dr. Mark Creighton-Gutteridge

    Head of Discovery and New Technologies, Oncology Cell Therapy Unit, GlaxoSmithKline, UK
  • Dr. Nicolas Fischer

    Head of Research, Novimmune
  • Prof. Dr. Thomas Valerius

    Medical Department II, Section on Stem Cell and Immunotherapy, University Hospital Schleswig – Kiel University, Germany
  • Dr. Maria Groves

    Head of CRUK-MEDI Alliance Laboratory, MedImmune
  • Dr. Randolf Kerschbaumer

    Director R&D, Antibody Technology Shire, Austria
  • Dr. Lioudmila Tchistiakova

    Senior Director-Global Biotherapeutic Technologies Pfizer BioTx, Maryland USA
  • Prof. Richard O’ Kennedy

    Professor of Biosciences- School of Biotechnology Dublin City University, Dublin
  • Prof. Angus Dalgleish

    Professor of Oncology, Chair of oncology -Institute of Infection and Immunity St. George’s University of London, UK
  • Dr. Charles Dumontet

    Adjunct Director of the Cancer Research Center of Lyon, Chair of the Research Council of the Hospices Civils de Lyon Cancer Research Center of Lyon, France
  • Dr. Lolke de Haan

    Director of Toxicology MedImmune, Cambridge, UK
  • Dr. Sonia Quaratino

    Global Clinical Program Leader, Novartis, Switzerland
  • Prof. Dr. Gabriele Multhoff

    Klinikum Rechts der Isar -Department of Radiation Oncology and Radiation Technical University of Munich, Germany
  • Dr. Johanna Olweus

    Director-K.G. Jebsen Centre for Cancer Immunotherapy Head-Department of Immunology- Institute for Cancer Research Oslo University Hospital Radium University of Oslo, Norway
  • Martin Schwill

    Phd- Department of Biochemistry-Laboratory of Prof. A. Plueckthun University of Zurich
  • Prof. Roland Kontermann

    Professor and Deputy Director -Biomedical Engineering, Institute of Cell Biology and Immunology University of Stuttgart, Germany
  • Dr. Martina Seiffert

    Team Leader CLL Tumor Microenvironment German Cancer Research Centre
  • Dr. Sine Reker Hadrup

    Associate Professor and section Head Immunology and Vaccinology Technical University of Denmark, Denmark
  • Dr. Roy Baynes

    Senior Vice President and Head, Global Clinical Development, Chief Medical Officer, MSD
  • Dr. Thierry Wurch

    Global Director - Antibody Projects Servier, France
  • Dr. Christian Ostheimer

    Dept. of Radiation Oncology-University Hospital Halle (UKH) Martin Luther University Halle-Wittenberg, Germany
  • Prof. Dr. Andre Frenzel

    Senior antibody engineering expert- Institute of Biochemistry, Biotechnology and Bioinformatics Technische Universität Braunschweig, Germany
  • Dr. Jens Lohrmann

    Senior Global Program Manager - Translational Clinical Oncology Novartis, Switzerland
  • Dr. Yvonne Andersson

    Scientist and Project leader: Anti-cancer therapy with immunotoxin Oslo University Hospital, Norway
  • Dr. Maxim Shevtsov

    Professor – Immunotherapy Group Klinikum rechts der Isar Technische Universität München, Germany
  • Dr Ahuva Nissim

    Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology Barts and The London, Queen Mary's School of Medicine and Dentistry , ohn Vane Science Centre, UK
  • Prof. Hardev Pandha

    Professor of Medical Oncology- Tumour Immunology University of Surrey, UK
  • Dr. Jeanette Leusen

    Associate professor and Head Immunotherapy group Laboratory for Translational Immunology University Medical Centre Utrecht, The Netherlands
  • Marlon J. Hinner

    Director, Immuno-Oncology Pieris Pharmaceuticals, Germany
  • Christoph Sachse

    Site Head Berlin, NMI TT Pharmaservices Natural Sciences and Medical Institute at the University of Tübingen, Germany
  • Alessandra Cesano

    Chief Medical Officer, NanoString Technologies
  • Matthew Baker

    VP, Immunology & Oncology Celentyx Ltd,UK
  • Ivan Diaz Padilla

    Global Clinical Leader Global Drug Development, Oncology Novartis Pharma AG, Switzerland
  • Payal Roychoudhury

    Field Applications Scientist, Maxcyte, Maryland USA
  • Steve Anderton

    Chief Scientific Officer, Aquila BioMedical, UK
  • Nathalie Faye

    Medical Director Median Technologies
  • Christine Schuberth-Wagner

    Senior Vice President, Research Rigontec GmbH, Germany
  • Carsten Corvey

    Group Leader, Global Bio therapeutics Sanofi, Germany
  • Mahendra Deonarain

    Chief Science and Operating Officer Antikor Biopharma Ltd, UK
  • Christophe Henry

    Project Lead, Translational Medicine Sanofi, France
  • Chris Allen

    Sr. Field Application Specialist Thermo Fisher Scientific, UK
  • Craig Malcolm

    Strategic Collaborations Manager Promega UK Ltd, UK


Gold Sponsor

NanoString TechnologiesNanoString Technologies

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is marketed for use on the nCounter Dx Analysis System which is FDA 510(k) cleared.

Silver Sponsor


MyCartis provides an open biomarker platform for fast and easy development and running of multiplex protein and molecular assays. Based on barcoded microparticles stacked in a microfluidic channel of a cartridge, the assays provide fast results while using simple workflows. Binding and detection reactions occur on-board of the instrument, providing a very robust and reproducible assay environment. This feature provides the unique capability to follow the binding reactions in real time
Aquila BioMedical

Aquila BioMedical

Aquila BioMedical is an innovative, preclinical contract research organisation, offering clients world-leading research expertise in immuno-oncology, immunology and multiplex histology.

We offer bespoke services, combining advanced models with protocolled techniques. The result? High-value data allowing you to define the efficacy and mechanism of action of your drug/antibody candidates. Partner with us to benefit from expert advice and data interpretation from superior and experienced scientists

Median TechnologiesMedian Technologies

Median Technologies is a full service imaging CRO for early and late phase oncology trials worldwide. We enable quantitative analysis of images and help standardize image interpretation for accurate measurement of tumor burden. Our technology allows for the management and direct comparison of multiple imaging endpoints and advanced biomarkers providing biopharmas with an unmatched level of meaningful insights and data integrity.


MaxCyte's flow electroporation is driving the next generation of cell-based medicines. Used in the discover, development, and manufacture of cell-based therapeutics, the MaxCyte GT® Flow Transfection System, MaxCyte STX® Scalable Transfection System, and MaxCyte VLX® Large Scale Transfection System enable the development of transfected cells for a range of applications.

Lonza - Sponsor of Next Gen Immuno-oncology Conference


Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration).

Posters should be presented as A0 or US equivalent, size E (841mm x

1189mm or 34 x 44 inches respectively) in portrait orientation.

For further details and requirements please contact:

Ajay Nimbalkar 

Email : ajay.nimbalkar@mnmconferences.com

Tel : +91 20 3010 8270

Academic delegatesFree
Industry and Solution Provider delegates£75

Posters Submission Form



The Antibody SocietyThe Antibody Society

The Antibody Society is a non-profit trade association representing individuals and organizations that operate in the antibody research and development area. We engage in activities that broadly benefit our members, such as education and publishing, and encourage collaboration between companies, academia and government organizations in the antibody field. We also help to organize conferences and networking events. As a trade association, the Society engages with government and international agencies to discuss issues of importance to the antibody community.    

 European Society of Surgical Oncology (ESSO)

European Society of Surgical Oncology (ESSO)
Representing a growing community of over 16,000 surgical oncologists worldwide,
the European Society of Surgical Oncology (ESSO) ensures the highest possible standard of surgical treatment to European cancer patients. Through its high-level annual Congress (ESSO 36 on 14-16 September 2016, Krakow; ESSO 37 on 27-01-17 in Amsterdam) and its widely recognised educational activities – including courses, meet-the-expert webinars, fellowships, quality assurance projects and its scientific journal EJSO - the Journal of Cancer Surgery – ESSO shares state-of-the-art knowledge and expertise since more than 35 years, to foster progress in surgical oncology and contribute to the continuous improvement of cancer treatment quality, accessibility and innovation.


C-KIN (Cancer & the Kidney International Network

C-KIN (Cancer & the Kidney International Network)

C-KIN (Cancer & the Kidney International Network)
 aims at improving patient care through better knowledge, education and awareness on cancer and the kidney related issues and research.

This ground-breaking network and association is the first truly international platform for oncologists, hematologists, supportive care specialists, nephrologists, hospital pharmacists, general practitioners, and all healthcare professionals working in the field.



MabDesign is a French membership organization that aims to structure, mobilize and support the development of the French industrial sector in the field of therapeutic antibody and immunotherapy.

MabDesign provides strategic leverage and development opportunities for its members.

These initiatives include:

-       the creation of a unique nationwide directory of antibody stakeholders allowing the identification of expertise and potential partners;

-       the access to innovative training solutions;

-       the business development and marketing support;

-       the organisation of events, thus promoting innovation and networking.

Cancer Drug Development Forum (CDDF)

The Cancer Drug Development Forum (CDDF)

The Cancer Drug Development Forum (CDDF) is an international organisation registered in Austria, providing a platform for all stakeholders involved in the development of oncology drugs. The aim of the not-for-profit organization is to accelerate the delivery of effective oncology agents to patients.

Established in 2001 as the Biotherapy Development Association (BDA), the focus was initially around immunotherapy. Recognizing the importance of embracing all forms of oncology drug development, the name of the organization was changed in 2014 to the Cancer Drug Development Forum (CDDF).

The CDDF, with its office based in Brussel, unites experts from academia, the pharmaceutical industry, regulatory authorities (including the EMA and FDA), payers (health technology assessors) and patient advocates.

At regular meetings and workshops, the CDDF creates an ideal scientific, regulatory and commercial environment for the clinical development of cancer drugs, and encourages a unique collaborative approach, where delegates engage in ‘frank and open’ discussions exploring innovative ideas in a ‘protected’ environment.

To know more about the association, please visit http://cddf.org and see the upcoming activities.

Congress is recommended by: 

ESTROFounded in 1980, ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organisation that fosters the role of Radiation Oncology in order to improve patients’ care in the multimodality treatment of cancer.

With over 6500 members in and outside Europe, ESTRO supports all the Radiation Oncology professionals in their daily practice: Radiation Oncologists, Medical Physicists, Radiobiologists and RTTs (Radiation TherapisTs) and the wider oncology community.

ESTRO’s mission is to promote innovation, research, and dissemination of science through its congresses, special meetings, educational courses and publications.



Next Gen Immuno-Oncology Congress will be held at the London Heathrow Marriott Hotel in United Kingdom.

London Heathrow Marriott Hotel

Heathrow Airport
140 Bath Road, Hayes
 Middlesex  UB3 5AW  England 
LAT: 51.481529 LONG: -0.441432

Hotel Booking Link

Accommodation is currently available at the London Heathrow Marriott Hotel at discounted rate. You will receive a link to book your accommodation via once you are fully registered. (Please note that we do not authorise any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on events@marketsandmarkets.com).

About the Hotel
The London Heathrow Marriott Hotel has well-designed guest rooms which are complemented by intuitive service and comfortable amenities. The hotel’s location, a half mile from Heathrow Airport, allows guests to rest easy and enjoy stress-free travel connections with the airport’s handy Hoppa Bus shuttle service. Just a short drive from Twickenham Stadium, our hotel puts guests near motorways and the Heathrow Express so London attractions are only minutes away. Soundproof guest rooms include plush bedding, 24-hour room service and premium movie channels along with in-room laptop safes and large work areas. Five on-site restaurants, an indoor pool and fully-equipped Leisure Club provide added comfort and relaxation. Boasting 8,719 square feet of innovative event space, professional event managers and catering staff our hotel sets the stage for successful business and social events. Whether travelling on holiday or for business, our hotel is an ideal destination.

For further Information please contact:
Email: events@marketsandmarkets.com